Argenx stock heads into the open after a modest 0.04% gain

At the close on September 13, 2026, Argenx stock on Euronext Amsterdam was around EUR 852.88 after a 0.04% daily gain, leaving the company with a market capitalization near EUR 53.03 billion. Today investors watch follow-up from its Morgan Stanley healthcare conference appearance.

Argenx stock closed at EUR 852.88 on Euronext Amsterdam on September 13, 2026, up 0.04% for the day, corresponding to a market capitalization of about EUR 53.03 billion. The move kept the shares near recent highs and in line with the broader European large-cap healthcare cohort.

September 13, 2026 in numbers

Argenx SE (ISIN NL0010832176) ended the September 13, 2026 session around EUR 852.88 per share on its European listing, with the one-day change of 0.04% fitting into a roughly 32.15% gain over the past year according to the market cap history overview at CompaniesMarketCap. The same data set indicates that Argenx’s market capitalization stood near EUR 53.03 billion as of September 2026, placing the company around the 410th most valuable listed group globally by market value. Over a longer horizon, the CompaniesMarketCap figures show that Argenx’s market cap has expanded from EUR 35.98 billion at the end of 2024 to EUR 53.03 billion in 2026, underscoring strong multi-year appreciation in the shares despite only modest single-day moves.

An analysis of Argenx stock performance on a German financial portal highlighted that, by September 11, 2026, a hypothetical EUR 10,000 investment made in 2016 would have grown to EUR 563,564.36, based on a last recorded price of EUR 853.80 per share and a cumulative gain of 5,535.64%. As that portal reported, recent trading around EUR 862.80 on September 11, 2026 came with a daily gain of 1.13% and a market capitalization near EUR 53.41 billion, illustrating how Argenx’s decade-long rise has been accompanied by continued investor interest and relatively high liquidity. According to the same German portal, Argenx is also held as a substantial position in specialized biotech funds, reinforcing its role as a core exposure within the sector.

Conference follow-up and today’s context

Today’s trading backdrop is shaped by Argenx’s appearance at Morgan Stanley’s 24th Annual Global Healthcare Conference, where management presented on September 14, 2026. As Seeking Alpha reported in its transcript of the session, Argenx used the event to discuss its strategy and pipeline in front of institutional investors at 9:15 a.m. EDT on September 14, 2026. A separate summary on Investing.com noted that Argenx featured prominently in the RTW Biotech Opportunities fund’s August 2026 factsheet, accounting for 6.1% of net asset value and ranking as one of the largest holdings, which supports the perception of Argenx as a key biotech name for professional portfolios.

Looking at upcoming developments, Argenx’s investor relations events calendar lists conference appearances and presentations but does not show a quarterly earnings release in the immediate days around September 15, 2026, suggesting that near-term share price drivers are more likely to stem from ongoing clinical updates, regulatory milestones and follow-through from the Morgan Stanley conference messaging. Against a backdrop of resilient biotechnology valuations and continued demand for antibody-based therapies, any new data or partnership news emerging around Argenx’s programs could add to the momentum that has already lifted the stock’s market capitalization to more than EUR 53 billion in 2026.